Mainz, May 2017 – On May 10, 2017, Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in cancer immunotherapy research. The Dutch immuno-haematologist is professor emeritus at Leiden University and Chairman of the Scientific Advisory Board of the Research Institute for Translational Oncology (TRON). The prize, which is endowed with 10,000 EUR, will be awarded for the first time by the Association for Cancer Immunotherapy CIMT on the occasion of the fifteenth anniversary of the Association at the Frankfurter Hof in Mainz, Germany.
Find more information on the official announcement at the CIMT website.
Mainz, May 2017 – On May 10, 2017, Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in cancer immunotherapy research.
Mainz, April - Mustafa Diken, PhD, presented on this year’s AACR conference 2017 our recent work on nanoparticles and RNA vaccine for cancer therapy. Immunotherapy has evolved as a promising alternative to conventional treatments against cancer. Thanks to its unique characteristics, mRNA can act not only as a source for antigen but also as an adjuvant for stimulating the immune system. Vaccination with tumor antigen-coding RNA has been shown to efficiently induce T cell responses and anti-tumor immunity in preclinical models and RNA-based vaccines are currently being tested in clinical trials with promising results.
Together with colleagues we have recently developed a novel class of systemically administered nanoparticulate RNA vaccines (RNA-LPX) acting by body-wide delivery of encoded antigens to APCs and simultaneous initiation of a strong type I IFN-driven immunostimulatory program. The RNA-to-lipid ratio was discovered to rule the biodistribution of RNA-LPX, irrespective of the types of lipids used, and a slightly negative particle net charge was enabling APC-specific internalization of RNA-LPX. RNA-LPX vaccines mimic the infectious non-self and thus mobilize both adaptive and innate immune mechanisms leading to strong effector and memory CD8 and CD4 T cell immunity against viral, mutant neo-antigens as well as self-antigens. These mechanisms were then able to reject progressive tumors in various mouse models of carcinoma. The simple but highly versatile design and production of RNA-LPX propose a universally applicable, first-in-class vaccine platform for cancer immunotherapy.
Mainz, April - Dr. Mustafa Diken presented on this year’s AACR conference 2017 our recent work on nanoparticles and RNA vaccine for cancer therapy.
Mainz, April - The 32nd Annual Meeting of the Rheumatology Working Group (ARRP) and the cooperative Rheumazentrum Rheinland-Pfalz e.V. was held in Bad Kreuznach from March 31 to April 1, 2017, to discuss the various aspects and current topics of rheumatology with a focus on interdisciplinary exchange!
Dr. Sebastian Boegel presented a poster of his work at TRON during the 32nd annual meeting. In particular, he spoke about the concept of precision medicine and the central role of Next Generation Sequencing and bioinformatic evaluation for the development of diagnostic, prevention and treatment strategies, taking into account the individual molecular variability of a patient. With his poster " Mit bioinformatischer Präzision dem Immunsystem auf der Spur ", Dr. Boegel mainly focused on the novel immunologically relevant applications of these technologies, since these are also of interest to rheumatologists.
Mainz, April - The 32nd Annual Meeting of the Rheumatology Working Group (ARRP) and the cooperative Rheumazentrum Rheinland-Pfalz e.V. ...
Mainz, March 2017 – On March 14, 2017 the 7th Ci3-Cluster conference took place in Mainz. The conference looked back at the successes resulting from the past five years of funding for projects in the Cluster for Individualized ImmunIntervention (Ci3) via the German Ministry for Education and Research (BMBF). Matthias Graf of Kielmansegg, Ministerialdirektor and Head of BMBF Abteilung 1 - Grundsatzfragen; Strategien; Digitaler Wandel, praised the extraordinary results of the Ci3 Cluster and emphasized the success of the entire BMBF Excellence Cluster program.
Graf von Kielmansegg, along with representatives from the project management organizations Jülich and VDI Technologiezentrum GmbH, also got the opportunity to visit TRON gGmbH in Mainz during their conference visit. At TRON, they were given a short overview over structure, mission, as well as technological and methodological competences established at the research institute, focusing on the longstanding collaboration and achievements with the BMBF. Although the limited time at TRON did not allow for a more detailed discussion, attention could also be directed to future perspectives of new, innovative therapy and diagnostic approaches in immunotherapy.
TRON wishes to thank Matthias Graf von Kielmansegg and the representatives of the project management agencies Jülich and VDI for their visit. More information on the BMBF can be found on their website (www.bmbf.de). Information regarding the Ci3 cluster as well as the press release for the 7th Cluster conference can be found under www.ci-3.de.
Mainz, March 2017 – On March 14, 2017 the 7th Ci3-Cluster conference took place in Mainz. The conference looked back at the successes resulting from the past five years of funding for projects in the Cluster for Individualized ImmunIntervention (Ci3) via the German Ministry for Education and Research (BMBF).
Mainz, March 2017 - The Research Institute for Translational Oncology (TRON) and the German Cancer Research Center (DKFZ) in Heidelberg join forces in a newly founded Helmholtz Institute for Translational Oncology (HI-TRON) at the University Medical Center Mainz. The aim of the partnership is to identify novel biomarkers, develop effective immunotherapies and facilitate their translation into the clinic.
Find more information on the new partnership in the official press release.
Mainz, March 2017 - The Research Institute for Translational Oncology (TRON) and the German Cancer Research Center (DKFZ) in Heidelberg join forces in a newly founded Helmholtz Institute for Translational Oncology (HI-TRON) at the University Medical Center Mainz.
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.
These are pretty dramatic results in the mouse model [of human cancers]. Studies like this are paving the way for effective vaccine approaches.
This study in mice provides the first evidence that we may be on the threshold of being able to produce individualised vaccines directed against specific mutations present in a patient’s tumour. Rapid production of purpose-built vaccines appears to be possible and can now be tested in carefully designed clinical trials. As yet, this approach must be seen as experimental but it potentially represents a new way of harnessing the power of the immune system against cancer.